BPC-157 TB-500 Questions, Answered From the Literature
Every answer maps to a cited study or the FDA record — the definitional, the mechanistic, the dose-context, the safety, and the regulatory questions about the Wolverine blend.
What the blend is
BPC-157 TB-500 questions cluster around one ambiguity: the blend is marketed as a single thing but studied as two. The answers below separate the per-component evidence from the blend-level claims, and cite the source for every quantitative point.
What is the BPC-157 and TB-500 blend used for in research?
In animal-model research the two peptides are studied separately for tissue repair: BPC-157 in tendon, ligament, muscle, and wound models [1], [5], [6], and TB-500 / Thymosin Beta-4 in actin-driven cell migration, wound, and angiogenesis models [4], [7]. The blend itself has no controlled-study indication.
What is the Wolverine peptide blend?
Wolverine is a research-community name for a two-peptide pairing of BPC-157 (a 15-amino-acid pentadecapeptide) and TB-500 (the synthetic Ac-LKKTETQ fragment of Thymosin Beta-4) [9]. It is not a single chemical entity or an approved product.
What is BPC-157 and TB-500?
BPC-157 is a synthetic stable fragment of a human gastric-juice protein studied as a cytoprotective and angiogenic signal; TB-500 is the synthetic actin-binding heptapeptide (residues 17-23) of Thymosin Beta-4 [3]. The blend co-formulates the two.
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The rationale pairs BPC-157's angiogenic-cytoprotective signal (VEGFR2-Akt-eNOS) [2] with TB-500's cytoskeletal actin-sequestration signal as complementary, largely non-overlapping mechanisms [4]. The "synergy" is a theoretical extrapolation, not a finding from a controlled combination study.
Mechanism and difference
How does TB-500 work (actin / Thymosin Beta-4)?
TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it — Thymosin Beta-4 caps both ends of the monomer — regulating the cytoskeletal dynamics that drive cell migration, re-epithelialization, and progenitor mobilization [3], [4].
How does BPC-157 work compared to TB-500?
BPC-157 supplies a local cytoprotective and pro-angiogenic signal — VEGFR2 up-regulation, Akt-eNOS, growth-hormone-receptor sensitization of fibroblasts [2], [5]; TB-500 supplies an intracellular actin-sequestration signal [3]. They act through complementary, largely separate pathways.
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid gastric-juice-derived pentadecapeptide acting on angiogenesis and cytoprotection [1]; TB-500 is a 7-amino-acid Ac-LKKTETQ fragment of Thymosin Beta-4 acting on actin and cell migration [3]. Different size, origin, and proposed mechanism.
Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
Both promote angiogenesis by distinct routes: BPC-157 via VEGFR2 up-regulation and the VEGFR2-Akt-eNOS pathway [2], and Thymosin Beta-4 via endothelial-migration angiogenesis [4]. Findings are from cell and animal models.
Does the BPC-157 TB-500 blend help wound healing?
Thymosin Beta-4 promotes re-epithelialization, reduces myofibroblast number (limiting scar), and is angiogenic in animal wound models [4], and BPC-157 has broad cytoprotective wound activity [2]; combined wound-healing efficacy in humans has not been studied.
Efficacy, evidence, and timeline
Does the BPC-157 TB-500 blend help tendon and ligament injuries?
BPC-157 accelerated healing of a transected rat Achilles tendon [1] and improved transected-tissue fibroblast outgrowth [5]; Thymosin Beta-4 enhanced rat MCL healing [8]. All findings are in animal models; no human tendon or ligament trial of the blend exists.
Does BPC-157 and TB-500 help muscle tears and recovery?
BPC-157 accelerated functional recovery of crushed rat gastrocnemius muscle [6], and injury-induced Thymosin Beta-4 acted as a myoblast chemoattractant [7]. These are rodent findings; combined human efficacy is unproven.
How long does it take BPC-157 and TB-500 to work for an injury?
Animal studies report tissue-level repair markers over days to weeks (transected-tendon [1], muscle-crush [6] models), but no validated human timeline exists for either peptide or the blend.
Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No. A 2025 systematic review of BPC-157 in orthopaedic sports medicine — 36 studies, only one human — makes no mention of TB-500 or combination use [10]; no peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together.
Are there human clinical trials on the BPC-157 + TB-500 combination?
No. Human data exist only for the individual constituents and are thin — three small BPC-157 pilots; full-length Thymosin Beta-4 Phase 1 studies, not the TB-500 7-mer. The combination's human efficacy and safety are unproven [12], [11].
Dose-context and safety
What is the half-life of BPC-157 and TB-500?
BPC-157 elimination half-life was reported under 30 minutes in a rat/dog pharmacokinetic study. No validated human half-life exists for the TB-500 heptapeptide or the blend; human intravenous full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics [4].
How do you cycle BPC-157 and TB-500?
No validated cycle exists for the blend. Community "loading then maintenance" protocols and fixed-ratio vials have no controlled-trial basis [10]; the published evidence is per-component and from animal models.
How much BPC-157 and TB-500 should be used per week?
There is no validated weekly dose for the blend. Rodent BPC-157 doses are commonly expressed per body weight (around 10 µg/kg) [1] and Thymosin Beta-4 doses span a wide range [4]; these are species-specific research figures, not human guidance.
How often should you inject BPC-157 and TB-500?
No validated injection frequency exists for the blend. The underlying rodent studies used various schedules (Thymosin Beta-4 twice weekly intraperitoneally in one six-month model) [4]; these are research designs, not human dosing instructions.
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated for research handling. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [9].
What are the side effects of BPC-157 and TB-500?
Human safety data for the blend are absent. A 2026 Sports Medicine review of unapproved musculoskeletal peptides, listing both compounds, notes scarce human safety data and potential for serious harm [11]; combining two unapproved peptides doubles that uncertainty.
Does TB-500 cause cancer or promote tumor growth?
Thymosin Beta-4 is overexpressed in several cancers and implicated in metastasis and tumor angiogenesis; the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [4]. This is a safety consideration, not a demonstrated effect of the blend.
Regulation and access
Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither is FDA-approved for human use; FDA's September 29, 2023 update put both in 503A Category 2, though its current page records their nominations as withdrawn [16], and both are WADA-prohibited. The WADA and FDA status is covered in full on the legal-status page.
Is Wolverine legal?
Neither component of the Wolverine blend is an FDA-approved drug, and the blend has no approved indication. The September 2023 FDA action placed both BPC-157 and TB-500 in 503A Category 2 because of stated safety concerns; on the agency's page current as of April 22, 2026, both are no longer in that category and appear under "Bulk drug substances nominated but withdrawn," while FDA has not explained what that entry permits a compounding pharmacy to provide [16], [15]. This is general regulatory information, not legal advice.
Can you get BPC-157 from a compounding pharmacy?
FDA placed BPC-157 in 503A Category 2 in September 2023 on its safety-risk rationale; the current page records that the nomination was later withdrawn, and the agency has not said whether that allows a pharmacy to compound it [16]. A compounder remains subject to the 503A/503B bulk-ingredient rules, although FDA has not spelled out how those rules apply to BPC-157 after its nomination was withdrawn [15]. BPC-157 also appeared on the July 23-24, 2026 PCAC agenda as a candidate; FDA's public record still carries no account of how that session ended [14].
What is the FDA 503A status of Wolverine?
Neither component is FDA-approved. FDA's September 29, 2023 update placed both BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in 503A Category 2; its current table records that both nominations were withdrawn rather than retaining either as a Category 2 entry [16]. Both were listed on the published agenda of the July 23-24, 2026 PCAC meeting as candidates for the 503A Bulks List; FDA staff had argued against adding them, and the agency has published no outcome [14]. The blend has no approved therapeutic indication.